C-reactive protein: a nontraditional serum marker of cardiovascular risk

Cardiovascular Pathology

Volumn 16, Issue 1, 2007, Pages 14-21

  de Ferranti, Sarah D ^a   Rifai, Nader ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

C reactive protein; Cardiovascular; Risk factor

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CYTOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC VALUE; FRAMINGHAM RISK SCORE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SECONDARY PREVENTION; STANDARDIZATION; STROKE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DISEASE-FREE SURVIVAL; HUMANS; RISK FACTORS;

EID: 33845980607     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carpath.2006.04.006     Document Type: Article

References (59)

1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337 (1997) 1360-1369
2. Kannel W. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 76 (1995) 69C-77C
3. Ridker P., Rifai N., Rose L., Buring J., and Cook N. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
4. Khot U., Khot M., Bajzer C., Sapp S., Ohman E., Brener S., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290 (2003) 898-904
5. Greenland P., Knoll M., Stamler J., Neaton J., Dyer A., Garside D., et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 290 (2003) 891-897
6. Libby P., Ridker P., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
7. Kimberly M., Vesper H., Caudill S., Cooper G., Rifai N., Dati F., et al. Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. Clin Chem 49 (2003) 611-616
8. Pearson T., Mensah G., Alexander R., Anderson J., Cannon R., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
9. Yasojima K., Schwab C., McGeer E., and McGeer P. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158 (2001) 1039-1051
10. Calabro P., Willerson J., and Yeh E. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108 (2003) 1930-1932
11. Lau D., Dhillon B., Yan H., Szmitko P., and Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288 (2005) H2031-H2041
12. Dollery C., Owen C., Sukhova G., Krettek A., Shapiro S., and Libby P. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation 107 (2003) 2829-2836
13. Vaughan D. Plasminogen activator inhibitor-1 and the calculus of mortality after myocardial infarction. Circulation 108 (2003) 376-377
14. Mach F., Schonbeck U., Bonnefoy J., Pober J., and Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 96 (1997) 396-399
15. Heinecke J. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 91 (2003) 12A-16A
16. Li H., Cybulsky M., Gimbrone M., and Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 13 (1993) 197-204
17. Barter P., Nicholls S., Rye K., Anantharamaiah G., Navab M., and Fogelman A. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
18. Liuzzo G., Biasucci L., Gallimore J., Grillo R., Rebuzzi A., Pepys M., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331 (1994) 417-424
19. Crea F., Monaco C., Lanza G., Maggi E., Ginnetti F., Cianflone D., et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clin Cardiol 25 (2002) 461-466
20. Packard C., O'reilly D., Caslake M., McMahon A., Ford I., Cooney J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000) 1148-1155
21. Ridker P., Cushman M., Stampfer M., Tracy R., and Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
22. Ridker P., Hennekens C., Buring J., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
23. Rost N., Wolf P., Kase C., Kelly-Hayes M., Silbershatz H., Massaro J., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32 (2001) 2575-2579
24. Wilson P., Nam B., Pencina M., D'Agostino R., Benjamin E., and O'Donnell C. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 165 (2005) 2473-2478
25. Greenland P., and O'Malley P. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med 165 (2005) 2454-2456
26. Koenig W., Sund M., Frohlich M., Fischer H., Lowel H., Doring A., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
27. Kuller L., Tracy R., Shaten J., and Meilahn E. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144 (1996) 537-547
28. Curb J., Abbott R., Rodriguez B., Sakkinen P., Popper J., Yano K., et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 107 (2003) 2016-2020
29. Ridker P., Stampfer M., and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 (2001) 2481-2485
30. Ridker P., Cushman M., Stampfer M., Tracy R., and Hennekens C. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97 (1998) 425-428
31. Ballantyne C., Hoogeveen R., Bang H., Coresh J., Folsom A., Heiss G., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
32. Albert M., and Ridker P. Inflammatory biomarkers in African Americans: a potential link to accelerated atherosclerosis. Rev Cardiovasc Med 5 Suppl 3 (2004) S22-S27
33. Sattar N., Gaw A., Scherbakova O., Ford I., O'reilly D., Haffner S., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
34. Lee W., Park J., Noh S., Rhee E., Sung K., Kim B., et al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 97 (2004) 101-106
35. Ridker P., Buring J., Cook N., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107 (2003) 391-397
36. Timpson N., Lawlor D., Harbord R., Gaunt T., Day I., Palmer L., et al. C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 366 (2005) 1954-1959
37. Calabro P., Chang D., Willerson J., and Yeh E. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 46 (2005) 1112-1113
38. Albert M., Danielson E., Rifai N., and Ridker P. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
39. Ridker P., and Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 109 (2004) 1955-1959
40. Ridker P., Cannon C., Morrow D., Rifai N., Rose L., McCabe C., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
41. Ridker P., Rifai N., Pfeffer M., Sacks F., Moye L., Goldman S., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators. Circulation 98 (1998) 839-844
42. Nissen S., Tuzcu E., Schoenhagen P., Crowe T., Sasiela W., Tsai J., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
43. Ridker P., Rifai N., Clearfield M., Downs J., Weis S., Miles J., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
44. Ridker P. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108 (2003) 2292-2297
45. Blake G., and Ridker P. Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. Ital Heart J 2 (2001) 796-800
46. Khreiss T., Jozsef L., Potempa L., and Filep J. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109 (2004) 2016-2022
47. Devaraj S., Venugopal S., and Jialal I. Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis 184 (2006) 48-52
48. Devaraj S., Du Clos T., and Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 25 (2005) 1359-1363
49. Venugopal S., Devaraj S., Yuhanna I., Shaul P., and Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106 (2002) 1439-1441
50. Liu C., Wang S., Deb A., Nath K., Katusic Z., McConnell J., et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circ Res 97 (2005) 135-143
51. Taylor K., Giddings J., and van den Berg C. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 25 (2005) 1225-1230
52. Singh U., Devaraj S., and Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 25 (2005) 2216-2221
53. Swafford A., Bratz I., Knudson J., Rogers P., Timmerman J., Tune J., et al. C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am J Physiol Heart Circ Physiol 288 (2005) H1786-H1795
54. van den Berg C., Taylor K., and Lang D. C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol 24 (2004) e168-e171
55. Lafuente N., Azcutia V., Matesanz N., Cercas E., Rodriguez-Manas L., Sanchez-Ferrer C., et al. Evidence for sodium azide as an artifact mediating the modulation of inducible nitric oxide synthase by C-reactive protein. J Cardiovasc Pharmacol 45 (2005) 193-196
56. Paul A., Ko K., Li L., Yechoor V., McCrory M., Szalai A., et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109 (2004) 647-655
57. Trion A., de Maat M., Jukema J., van der L., Maas M., Offerman E., et al. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-Leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol 25 (2005) 1635-1640
58. Reifenberg K., Lehr H., Baskal D., Wiese E., Schaefer S., Black S., et al. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer?. Arterioscler Thromb Vasc Biol 25 (2005) 1641-1646
59. Danesh J., Wheeler J., Hirschfield G., Eda S., Eiriksdottir G., Rumley A., Lowe G., Pepys M., and Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 14 (2004) 1387-1397